Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemafibrate for post-pancreaticoduodenectomy refractory steatotic liver disease
jRCTs061240078Recruiting
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of pemafibrate in steatosis (2 arms). Primary endpoint: Percentage of patients with liver CT value ≥40 HU at 24 weeks. Started Jan 2025; status: recruiting.
02
Drugs
pemafibrate
03
Conditions
steatosis
Beyond the preview
Go deeper on jRCTs061240078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061240078.